<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599374</url>
  </required_header>
  <id_info>
    <org_study_id>THs</org_study_id>
    <nct_id>NCT04599374</nct_id>
  </id_info>
  <brief_title>the Association Between Thyroid Hormones and Metabolic Components in Patients With Obesity</brief_title>
  <official_title>the Association Between Thyroid Hormones and Metabolic Components in Patients With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collected clinical data of obese patients with euthyroid function, including age,&#xD;
      gender, height, weight, BMI, waist circumference, blood pressure, fasting blood sugar, blood&#xD;
      sugar 2 hours after sugar load, fasting plasma high-density lipoprotein cholesterol, fasting&#xD;
      three acyl glycerin, free iodine thyroid hormone (FT3) and free thyroid hormones (FT4),&#xD;
      thyroid stimulating hormone (TSH), follow-up information and etc. Via analyzing the data, the&#xD;
      investigators want to investigate the association between thyroid hormones (THs) and&#xD;
      metabolic components in obese patients with euthyroid function and to present the cutoff&#xD;
      values of THs in order to provide new information for the risk stratification of metabolic&#xD;
      syndrome in obese patients with euthyroid function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>meet the criteria of metabolism in the 2017 Chinese guideline</measure>
    <time_frame>2015-2020</time_frame>
    <description>Abdominal obesity (or central obesity), male abdominal circumference ≥90cm, female abdominal circumference ≥85 cm;&#xD;
Hypertension, those who have been diagnosed with hypertension and are in treatment and (or) blood pressure ≥130/85mmHg (1mmHg = 0.133kPa);&#xD;
Hyperglycemia, those who have been diagnosed with diabetes and are treated and (or) fasting blood glucose ≥6.1mmol/L or 2h blood glucose ≥7.8mmol/L after glucose load;&#xD;
Fasting high-density lipoprotein cholesterol (HDL-C) &lt;1.04mmol/L;&#xD;
Fasting triacylglycerol ≥1.70mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high uric acid</measure>
    <time_frame>2015-2020</time_frame>
    <description>female patients with uric acid over 360 umol/L and male female patients with uric acid over 420 umol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FBG≥6.1mmol/L</measure>
    <time_frame>2015-2020</time_frame>
    <description>patients with fasting blood glucose 6.1mmol/L or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BG120≥7.8mmol/L</measure>
    <time_frame>2015-2020</time_frame>
    <description>patients with 2 hour blood glucose 7.8mmol/L or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FINS≥24.9 pmol/ml</measure>
    <time_frame>2015-2020</time_frame>
    <description>patients with fasting insulin 24.9 pmol/ml or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FCP≥4.4nmol/L</measure>
    <time_frame>2015-2020</time_frame>
    <description>patients with fasting C-peptide 4.4nmol/L or more.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">373</enrollment>
  <condition>Obesity</condition>
  <condition>Euthyroid Condition</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>high TSH and high FT4</arm_group_label>
    <description>patients with high TSH and high FT4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high TSH and low FT4</arm_group_label>
    <description>patients with high TSH and low FT4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high TSH and high FT3</arm_group_label>
    <description>patients with high TSH and high FT3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high TSH and low FT3</arm_group_label>
    <description>patients with high TSH and low FT3</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>This study collected data only without any intervention.</description>
    <arm_group_label>high TSH and high FT3</arm_group_label>
    <arm_group_label>high TSH and high FT4</arm_group_label>
    <arm_group_label>high TSH and low FT3</arm_group_label>
    <arm_group_label>high TSH and low FT4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We enrolled obese patients with euthyroid function.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) age ranged from 18-65 years old, 2) BMI over 27.9kg/m2,3)TSH，FT4, and FT3 within&#xD;
             the range of 0.38-4.34mIU/L, 10.5-24.4mIU/L, and 2.8-6.3mIU/L, respectively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary cause of obesity such as hypothalamic obesity, Cushing syndrome, and&#xD;
             hypophysis dysfunction, etc.,2)pregnancy or location, 3) severe heart, liver and&#xD;
             kidney dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Shen Qu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data (IPD) are not available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

